Related references
Note: Only part of the references are listed.Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML
Johan Aurelius et al.
LEUKEMIA & LYMPHOMA (2019)
Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade
Hanna Grauers Wiktorin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Gregory W. Roloff et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Role of NOX2-Derived Reactive Oxygen Species in NK Cell-Mediated Control of Murine Melanoma Metastasis
Ebru Aydin et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Dendritic Cell Therapies for Hematologic Malignancies
Matthew Weinstock et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia
Anna Martner et al.
ONCOIMMUNOLOGY (2016)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunotherapeutic strategies for relapse control in acute myeloid leukemia
Anna Martner et al.
BLOOD REVIEWS (2013)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
Mats Brune et al.
BLOOD (2006)
Share Paper
